|
Characteristic
|
Number of patients (%)
|
|---|
|
Age (years)
|
|
< 40
|
9 (10.0)
|
|
≥ 40 to < 60
|
64 (71.1)
|
|
≥ 60
|
17 (18.9)
|
|
Menstrual status
|
|
Premenopausal
|
31 (34.4)
|
|
Menopausal
|
59 (65.6)
|
|
ER status
|
|
Positive
|
71 (78.9)
|
|
Negative
|
19 (21.1)
|
|
PR status
|
|
Positive
|
66 (73.3)
|
|
Negative
|
24 (26.7)
|
|
HR status
|
|
Positive
|
74 (82.2)
|
|
Negative
|
16 (17.8)
|
|
Disease-free survival (months)
|
|
≤ 12
|
18 (20.0)
|
|
> 12 to ≤ 24
|
9 (10.0)
|
|
> 24 to ≤ 60
|
34 (37.8)
|
|
> 60
|
29 (32.2)
|
|
Number of metastases
|
|
Single
|
4 (4.4)
|
|
Multiple
|
86 (95.6)
|
|
Position of metastatic site
|
|
Non-visceral
|
31 (34.4)
|
|
Visceral
|
59 (65.6)
|
|
Previous endocrinotherapy (after confirmed tumor relapse)
|
|
None
|
71 (78.9)
|
|
First-line
|
15 (16.7)
|
|
Second-line or more
|
4 (4.4)
|
- CTCs circulating tumor cells, HER2 human epidermal growth factor receptor 2, ER estrogen receptor, PR progestrone receptor, HR hormone receptor
